A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

• Status: Completed
• Trial end date: 2003-01-16
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Alendronate; Raloxifene Hydrochloride

Criteria

Inclusion Criteria:

• Patient is postmenopausal (or surgically menopausal) for at least 6 months

• Patient must be diagnosed with osteoporosis

• Patient has spinal anatomy suitable for DEXA of the lumbar spine

Exclusion Criteria:

• Patient is receiving or has received treatment prior to randomization which might influence bone turnover

• Patient has a history of or evidence for metabolic bone disease (other than postmenopausal bone loss)

• Patient is receiving or is expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism